Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 5/20 | 0.63 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11264693 | 0.86 | GAA (0.57) | HTR6GAACA9CA12CA1 | |
| SCHEMBL34558 | 0.84 | HTR6 (0.77) | HTR6GAACA9CA12CA1 | |
| SCHEMBL30751995 | 0.84 | HTR6 (1.00) | HTR6GAACA9CA12CA1 | |
| SCHEMBL395274 | 0.84 | HTR6 (1.00) | HTR6GAACA9CA12CA1 | |
| SCHEMBL5676916 | 0.81 | CA2 (0.68) | HTR6GAACA9CA12CA1 | |
| SCHEMBL9464499 | 0.81 | HTR6 (0.71) | HTR6GAACA9CA12CA1 | |
| SCHEMBL2004711 | 0.81 | HTR6 (0.71) | HTR6GAACA9CA12CA1 | |
| SCHEMBL29381324 | 0.80 | GAA (0.61) | HTR6GAACA9CA12CA1 | |
| SCHEMBL28164 | 0.80 | GAA (0.61) | HTR6GAACA9CA12CA1 | |
| Alcohol SCHEMBL27500513 | 0.79 | HTR6 (0.62) | HTR6GAACA9CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10973831-B2 | Fluoropiperidine compounds as pure 5-HT 6 receptor antagonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-04-13 | — | — | US | disclosed |
| EP-3649124-B1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2021-03-03 | — | — | EP | disclosed |
| US-20200155560-A1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT 6 RECEPTOR ANTAGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2020-05-21 | — | — | US | disclosed |
| EP-3649124-A1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONISTS | Suven Life Sciences Limited (IN) | 2020-05-13 | — | — | EP | disclosed |
| WO-2019030641-A1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155560-A1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT 6 RECEPTOR ANTAGONISTS | HTR6, HTR5A, HTR1B | HTR6 1/4885GAA 3728/4885CA9 4007/4885 |
| US-10973831-B2 | Fluoropiperidine compounds as pure 5-HT 6 receptor antagonists | HTR6, HTR5A, HTR1B | HTR6 1/4885GAA 3728/4885CA9 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.